Concepedia

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum

Journal of Clinical Oncology · 2000 · 915 citations · 13 references

DOI

Abstract

The results of the intergroup E1690 trial demonstrate an RFS benefit of IFNalpha2b that is dose-dependent and significant for HDI by Cox multivariable analysis.

References

13

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

J M Kirkwood, M H Strawderman, Marc S. Ernstoff et al. · Journal of Clinical Oncology · 1996 · 2.1K citations

Model Predicting Survival in Stage I Melanoma Based on Tumor Progression

W. H. Clark, David E. Elder, DuPont Guerry et al. · JNCI Journal of the National Cancer Institute · 1989 · 1.2K citations

A Multifactorial Analysis of Melanoma

Charles M. Balch, Tariq M. Murad, Seng‐Jaw Soong et al. · Annals of Surgery · 1978 · 574 citations · Full text

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

Jean‐Jacques Grob, Brigitte Dréno, Pauline de La Salmonière et al. · The Lancet · 1998 · 435 citations

, , +6

A Multifactorial Analysis of Melanoma

Charles M. Balch, Seng‐Jaw Soong, Tariq M. Murad et al. · Annals of Surgery · 1981 · 367 citations · Full text